Purpose The purpose of this analysis was to assess the cost-effectiveness of apixaban 5 mg
BID versus high-and low-dose edoxaban (60 mg and 30 mg once daily) as intended starting …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

Objective To conduct a systematic review of economic models of newer anticoagulants for
stroke prevention in atrial fibrillation (SPAF). Patients and Methods We searched Medline …

ABSTRACT BACKGROUND: Apixaban, an oral anticoagulant for stroke and systemic
embolism prevention in non-valvular atrial fibrillation (NVAF), was superior to warfarin in …

Purpose The aim of this study was to evaluate the cost-effectiveness of apixaban compared
with to warfarin, current standard of care, for stroke prevention in patients with nonvalvular …

Introduction and objectives Cost-effectiveness analysis of apixaban (5 mg twice daily) vs
acenocoumarol (5 mg/day) in the prevention of stroke in patients with nonvalvular atrial …

Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …

Objective To determine the cost-effectiveness of apixaban versus warfarin in patients with
atrial fibrillation (AF) with a moderate to severe risk of stroke, from an Australian government …

Objectives Many of the cost-effectiveness analyses of apixaban against warfarin focused on
Western populations but Asian evidence remains less clear. The present study aims to …

Objectives: To conduct an economic evaluation of the currently prescribed treatments for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin …